RESTATEMENT OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL STATEMENTS - RESTATED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
Balance beginning | $ (8,387,900) | $ 1,370,983 | $ 8,153,244 | $ 17,912,049 | $ 23,127,139 | $ 29,063,131 | $ 8,153,244 | $ 29,063,131 | $ 8,153,244 | $ 29,063,131 | $ 8,153,244 | $ 29,063,131 |
Balance beginning Series D preferred stock | 1,382,023 | 1,382,023 | 1,382,023 | 1,382,023 | ||||||||
Balance beginning Series D preferred stock (in shares) | ||||||||||||
Stock-based compensation (Note7) | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | ||||
Exercise of warrants into common shares | 649,250 | 2,467,222 | ||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 9,429,767 | |||||||||||
Reclassification of pre-funded warrants to liability | (3,239,112) | (3,239,112) | ||||||||||
Net loss | (17,520,378) | (10,178,640) | (7,190,470) | (7,511,322) | (5,635,043) | (6,239,797) | (17,369,110) | (11,874,840) | (34,889,488) | (19,386,162) | (42,770,610) | (31,792,618) |
Balance ending Series D preferred stock | 19,202,023 | 1,382,023 | 19,202,023 | 1,382,023 | $ 1,382,023 | 1,382,023 | ||||||
Balance ending Series D preferred stock (in shares) | 111.11 | |||||||||||
Balance ending | (28,000,262) | (8,387,900) | 1,370,983 | 10,768,486 | 17,912,049 | 23,127,139 | (8,387,900) | 17,912,049 | (28,000,262) | 10,768,486 | $ (15,158,968) | 8,153,244 |
As previously reported | ||||||||||||
Balance beginning | (467,004) | 7,334,461 | 15,507,519 | 20,194,072 | 27,209,162 | 33,045,154 | 15,507,519 | 33,045,154 | 15,507,519 | 33,045,154 | 15,507,519 | 33,045,154 |
Stock-based compensation (Note7) | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | ||||
Exercise of warrants into common shares | 348,638 | 789,642 | ||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 17,920,000 | 9,610,655 | ||||||||||
Net loss | (13,732,350) | (8,221,222) | (8,581,267) | (7,811,322) | (7,435,043) | (6,139,797) | (16,802,489) | (13,574,840) | (30,534,839) | (21,386,162) | (37,983,496) | (28,601,254) |
Balance ending Series D preferred stock | 17,920,000 | 17,920,000 | ||||||||||
Balance ending | (13,352,838) | (467,004) | 7,334,461 | 12,750,509 | 20,194,072 | 27,209,162 | (467,004) | 20,194,072 | (13,352,838) | 12,750,509 | (1,356,047) | 15,507,519 |
Restatement adjustments | ||||||||||||
Balance beginning | (7,920,896) | (5,963,478) | (7,354,275) | (2,282,023) | (4,082,023) | (3,982,023) | (7,354,275) | (3,982,023) | (7,354,275) | (3,982,023) | (7,354,275) | (3,982,023) |
Balance beginning Series D preferred stock | 1,382,023 | 1,382,023 | 1,382,023 | 1,382,023 | ||||||||
Exercise of warrants into common shares | 300,612 | 1,677,580 | ||||||||||
Reclassification of pre-funded warrants to liability | (3,239,112) | (3,239,112) | (7,005,493) | |||||||||
Net loss | (3,788,028) | (1,957,418) | 1,390,797 | 300,000 | 1,800,000 | (100,000) | (566,621) | 1,700,000 | (4,354,649) | 2,000,000 | (4,787,114) | (3,191,364) |
Balance ending Series D preferred stock | 1,282,023 | 1,382,023 | 1,282,023 | 1,382,023 | 1,382,023 | 1,382,023 | ||||||
Balance ending | $ (14,647,424) | (7,920,896) | (5,963,478) | (1,982,023) | (2,282,023) | (4,082,023) | (7,920,896) | (2,282,023) | (14,647,424) | (1,982,023) | (13,802,921) | (7,354,275) |
Series D Preferred stock | ||||||||||||
Balance beginning Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | ||
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | ||
Balance ending Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | |||||
Balance ending Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | |||
Series D Preferred stock | Restatement adjustments | ||||||||||||
Balance beginning Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | ||
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | ||
Balance ending Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | |||||
Balance ending Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | |||||
Series E-1 preferred stock | ||||||||||||
Balance ending Series D preferred stock (in shares) | 1,225 | 1,225 | ||||||||||
Series E-2 Preferred Stock | ||||||||||||
Aggregate value of shares issued | $ 17,820,000 | |||||||||||
Series E-2 Preferred Stock | Restatement adjustments | ||||||||||||
Aggregate value of shares issued | (100,000) | |||||||||||
Preferred Stock | ||||||||||||
Balance beginning | ||||||||||||
Balance beginning (in shares) | ||||||||||||
Conversion of preferred stock to common stock | $ (13,142,368) | |||||||||||
Conversion of preferred stock to common stock (in shares) | (905.24) | |||||||||||
Balance ending | $ 4,677,632 | |||||||||||
Balance ending (in shares) | 319.76 | |||||||||||
Preferred Stock | As previously reported | ||||||||||||
Balance beginning | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 |
Balance beginning (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 |
Conversion of preferred stock to common stock | $ (13,242,368) | |||||||||||
Conversion of preferred stock to common stock (in shares) | (905.24) | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 17,920,000 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225.00 | |||||||||||
Balance ending | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 6,059,655 | $ 1,382,023 |
Balance ending (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 430.87 | 111.11 |
Preferred Stock | Restatement adjustments | ||||||||||||
Balance beginning | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) |
Balance beginning (in shares) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) |
Conversion of warrants into common shares | $ 100,000 | |||||||||||
Balance ending | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) | $ (1,382,023) |
Balance ending (in shares) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) | (111.11) |
Preferred Stock | Series D and Series E-1 Preferred Stock | ||||||||||||
Balance beginning Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | ||||||
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | ||||||
Balance ending Series D preferred stock | $ 19,202,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 19,202,023 | $ 1,382,023 | ||||||
Balance ending Series D preferred stock (in shares) | 1,336.11 | 111.11 | 111.11 | 111.11 | 1,336.11 | 111.11 | ||||||
Preferred Stock | Series D and Series E-1 Preferred Stock | As previously reported | ||||||||||||
Balance ending Series D preferred stock | $ 17,920,000 | $ 17,920,000 | ||||||||||
Balance ending Series D preferred stock (in shares) | 1,225.00 | 1,225.00 | ||||||||||
Preferred Stock | Series D and Series E-1 Preferred Stock | Restatement adjustments | ||||||||||||
Balance beginning Series D preferred stock | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | ||||||
Balance beginning Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | ||||||
Balance ending Series D preferred stock | $ 1,282,023 | $ 1,382,023 | $ 1,382,023 | $ 1,382,023 | $ 1,282,023 | $ 1,382,023 | ||||||
Balance ending Series D preferred stock (in shares) | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | 111.11 | ||||||
Preferred Stock | Series E-1 preferred stock | ||||||||||||
Aggregate value of shares issued | $ 17,820,000 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225.00 | |||||||||||
Preferred Stock | Series E-1 preferred stock | As previously reported | ||||||||||||
Aggregate value of shares issued | $ 17,920,000 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225.00 | |||||||||||
Preferred Stock | Series E-1 preferred stock | Restatement adjustments | ||||||||||||
Aggregate value of shares issued | $ (100,000) | |||||||||||
Preferred Stock | Series E-2 Preferred Stock | ||||||||||||
Aggregate value of shares issued | $ 17,820,000 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 1,225.00 | |||||||||||
Preferred Stock | Series E-2 Preferred Stock | Restatement adjustments | ||||||||||||
Aggregate value of shares issued | $ (100,000) | |||||||||||
Common Stock | ||||||||||||
Balance beginning | $ 97 | $ 97 | $ 94 | $ 61 | $ 61 | $ 61 | $ 94 | $ 61 | $ 94 | $ 61 | $ 94 | $ 61 |
Balance beginning (in shares) | 9,740,507 | 9,740,507 | 9,385,272 | 6,110,122 | 6,110,124 | 6,110,125 | 9,385,272 | 6,110,125 | 9,385,272 | 6,110,125 | 9,385,272 | 6,110,125 |
Exercise of warrants into common shares | $ 2 | $ 12 | ||||||||||
Exercise of warrants into common shares (in shares) | 177,877 | 1,197,622 | ||||||||||
Conversion of preferred stock to common stock | $ 99 | |||||||||||
Conversion of preferred stock to common stock (in shares) | 9,947,684 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 33 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 3,275,153 | |||||||||||
Retired shares (in shares) | (4) | (2) | (1) | 6 | ||||||||
Balance ending | $ 99 | $ 97 | $ 97 | $ 61 | $ 61 | $ 61 | $ 97 | $ 61 | $ 99 | $ 61 | $ 207 | $ 94 |
Balance ending (in shares) | 9,918,384 | 9,740,507 | 9,740,507 | 6,110,118 | 6,110,122 | 6,110,124 | 9,740,507 | 6,110,122 | 9,918,384 | 6,110,118 | 20,744,110 | 9,385,272 |
Common Stock | As previously reported | ||||||||||||
Balance beginning | $ 97 | $ 97 | $ 94 | $ 61 | $ 61 | $ 61 | $ 94 | $ 61 | $ 94 | $ 61 | $ 94 | $ 61 |
Balance beginning (in shares) | 9,740,507 | 9,740,507 | 9,385,272 | 6,110,122 | 6,110,124 | 6,110,125 | 9,385,272 | 6,110,125 | 9,385,272 | 6,110,125 | 9,385,272 | 6,110,125 |
Exercise of warrants into common shares | $ 2 | $ 12 | ||||||||||
Exercise of warrants into common shares (in shares) | 177,877 | 1,197,622 | ||||||||||
Conversion of preferred stock to common stock | $ 99 | |||||||||||
Conversion of preferred stock to common stock (in shares) | 9,947,684 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 33 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) | 3,275,153 | |||||||||||
Retired shares (in shares) | (4) | (2) | (1) | (6) | ||||||||
Balance ending | $ 99 | $ 97 | $ 97 | $ 61 | $ 61 | $ 61 | $ 97 | $ 61 | $ 99 | $ 61 | $ 207 | $ 94 |
Balance ending (in shares) | 9,918,384 | 9,740,507 | 9,740,507 | 6,110,118 | 6,110,122 | 6,110,124 | 9,740,507 | 6,110,122 | 9,918,384 | 6,110,118 | 20,744,110 | 9,385,272 |
Additional Paid-In Capital | ||||||||||||
Balance beginning | $ 168,971,520 | $ 168,551,763 | $ 168,143,557 | $ 157,984,617 | $ 157,564,664 | $ 157,260,859 | $ 168,143,557 | $ 157,260,859 | $ 168,143,557 | $ 157,260,859 | $ 168,143,557 | $ 157,260,859 |
Stock-based compensation (Note7) | $ 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | ||||
Exercise of warrants into common shares | 2,467,210 | |||||||||||
Exercise of warrants into common shares (in shares) | 649,248 | |||||||||||
Conversion of preferred stock to common stock | 13,142,269 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 9,429,734 | |||||||||||
Reclassification of pre-funded warrants to liability | $ (3,239,112) | (3,239,112) | ||||||||||
Balance ending | 166,879,534 | 168,971,520 | 168,551,763 | 158,352,376 | 157,984,617 | 157,564,664 | 168,971,520 | 157,984,617 | 166,879,534 | 158,352,376 | 182,924,210 | 168,143,557 |
Additional Paid-In Capital | As previously reported | ||||||||||||
Balance beginning | 194,452,408 | 194,032,651 | 193,624,445 | 183,284,617 | 182,864,664 | 182,560,859 | 193,624,445 | 182,560,859 | 193,624,445 | 182,560,859 | 193,624,445 | 182,560,859 |
Stock-based compensation (Note7) | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 2,410,288 | 1,452,964 | ||||
Exercise of warrants into common shares | 348,636 | 789,630 | ||||||||||
Conversion of preferred stock to common stock | 13,242,269 | |||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 9,610,622 | |||||||||||
Balance ending | 195,298,922 | 194,452,408 | 194,032,651 | 183,652,376 | 183,284,617 | 182,864,664 | 194,452,408 | 183,284,617 | 195,298,922 | 183,652,376 | 210,066,630 | 193,624,445 |
Additional Paid-In Capital | Restatement adjustments | ||||||||||||
Balance beginning | (25,480,888) | (25,480,888) | (25,480,888) | (25,300,000) | (25,300,000) | (25,300,000) | (25,480,888) | (25,300,000) | (25,480,888) | (25,300,000) | (25,480,888) | (25,300,000) |
Exercise of warrants into common shares | 300,612 | 1,677,580 | ||||||||||
Reclassification of pre-funded warrants to liability | (3,239,112) | (3,239,112) | (7,005,493) | |||||||||
Conversion of warrants into common shares | (100,000) | |||||||||||
Balance ending | (28,419,388) | (25,480,888) | (25,480,888) | (25,300,000) | (25,300,000) | (25,300,000) | (25,480,888) | (25,300,000) | (28,419,388) | (25,300,000) | (27,142,420) | (25,480,888) |
Accumulated Deficit | ||||||||||||
Balance beginning | (177,359,517) | (167,180,877) | (159,990,407) | (140,072,629) | (134,437,586) | (128,197,789) | (159,990,407) | (128,197,789) | (159,990,407) | (128,197,789) | (159,990,407) | (128,197,789) |
Net loss | (17,520,378) | (10,178,640) | (7,190,470) | (7,511,322) | (5,635,043) | (6,239,797) | (42,770,610) | (31,792,618) | ||||
Balance ending | (194,879,895) | (177,359,517) | (167,180,877) | (147,583,951) | (140,072,629) | (134,437,586) | (177,359,517) | (140,072,629) | (194,879,895) | (147,583,951) | (202,761,017) | (159,990,407) |
Accumulated Deficit | As previously reported | ||||||||||||
Balance beginning | (196,301,532) | (188,080,310) | (179,499,043) | (164,472,629) | (157,037,586) | (150,897,789) | (179,499,043) | (150,897,789) | (179,499,043) | (150,897,789) | (179,499,043) | (150,897,789) |
Net loss | (13,732,350) | (8,221,222) | (8,581,267) | (7,811,322) | (7,435,043) | (6,139,797) | (37,983,496) | (28,601,254) | ||||
Balance ending | (210,033,882) | (196,301,532) | (188,080,310) | (172,283,951) | (164,472,629) | (157,037,586) | (196,301,532) | (164,472,629) | (210,033,882) | (172,283,951) | (217,482,539) | (179,499,043) |
Accumulated Deficit | Restatement adjustments | ||||||||||||
Balance beginning | 18,942,015 | 20,899,433 | 19,508,636 | 24,400,000 | 22,600,000 | 22,700,000 | 19,508,636 | 22,700,000 | 19,508,636 | 22,700,000 | 19,508,636 | 22,700,000 |
Net loss | (3,788,028) | (1,957,418) | 1,390,797 | 300,000 | 1,800,000 | (100,000) | (4,787,114) | (3,191,364) | ||||
Balance ending | $ 15,153,987 | $ 18,942,015 | 20,899,433 | $ 24,700,000 | $ 24,400,000 | $ 22,600,000 | $ 18,942,015 | $ 24,400,000 | $ 15,153,987 | $ 24,700,000 | $ 14,721,522 | 19,508,636 |
Pre-funded warrants | ||||||||||||
Conversion of warrants into common shares | 3 | |||||||||||
Pre-funded warrants | As previously reported | ||||||||||||
Conversion of warrants into common shares | 3 | |||||||||||
Pre-funded warrants | Common Stock | ||||||||||||
Conversion of warrants into common shares | $ 3 | |||||||||||
Conversion of warrants into common shares (in shares) | 355,235 | |||||||||||
Pre-funded warrants | Common Stock | As previously reported | ||||||||||||
Conversion of warrants into common shares | $ 3 | |||||||||||
Conversion of warrants into common shares (in shares) | 355,235 | |||||||||||
Warrants | Restatement adjustments | ||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | 6,824,605 | |||||||||||
Warrants | Additional Paid-In Capital | Restatement adjustments | ||||||||||||
Issuance of common stock and pre-funded warrants net of issuance costs | $ 6,824,605 |